Rituximab in the Treatment of Thyroid Eye Disease: A Review

ABSTRACT

Graves disease is an autoimmune thyroid disease classically characterised by a clinical triad consisting of hyperthyroidism, diffuse goitre, and thyroid eye disease. Thyroid eye disease is an immunologically mediated condition in which humoral immunity is thought to play a central role. Thyroid eye disease is traditionally treated with high-dose glucocorticosteroids and surgical orbital decompression. However, responses are inadequate and alternative treatment options are needed. Rituximab, an anti-CD20 monoclonal antibody, shows promise as a novel therapeutic option for thyroid eye disease. There are 43 cases of thyroid eye disease treated with rituximab in the medical literature, and larger studies are warranted to determine the long-term effectiveness of rituximab. Rituximab may represent an attractive new treatment option for thyroid eye disease, especially in the case of disease that is refractory to current treatment strategies.

• Biologic therapy
• Graves disease
• Graves orbitopathy
• ophthalmopathy rituximab
• thyroid-associated orbitopathy
• thyroid eye disease

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.